Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions
Phase 3
Completed
- Conditions
- Primary HypogonadismHypogonadotropic Hypogonadism
- Interventions
- Registration Number
- NCT02110368
- Lead Sponsor
- Amneal Pharmaceuticals, LLC
- Brief Summary
Bioequivalence study comparing the rate and extent of testosterone absorption for a test formulation versus the reference product.
- Detailed Description
To compare the rate and extent of testosterone absorption for a test formulation of Testosterone Topical Gel, 1.62% Metered Pump, manufactured with that of AndroGel® (testosterone gel) 1.62% Metered-Dose Pump, in normal, healthy, adult, testosterone-deficient (hypogonadal) human male subjects under fasting conditions.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 32
Inclusion Criteria
- Healthy adult men with hypogonadism with testosterone levels <250ng/dL
- 18 to 65 years of age (inclusive)
- Have normal PSA < 4.0ng/mL
- Weighing a minimum of 50 kg and having a body mass index between 18.0 and 38.0 kg/m2.
- Good health as determined by medical history and lack of clinically significant abnormalities (other than hypogonadism).
- Vital signs, must be within the following ranges heart rate: 45-100 bpm; systolic BP: 90-150 mmHg; diastolic BP: 50-90 mmHg. Out-of-range vital signs may be repeated.
Read More
Exclusion Criteria
- Is female
- History of allergy or sensitivity to AndroGel® or any component of drug or a related testosterone drug, Axiron®, Testim®, etc.
- History of allergy or intolerance to soy, soybean, and/or soy lecithin
- History of any drug or food hypersensitivity or intolerance which, would compromise the safety of the subject or the study.
- History or presence of clinically significant ocular, cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any othercondition that, would jeopardize the safety of the subject or the validity of the study results.
- Had no major surgery or illness within 3 months before screening.
- History or presence of benign prostate hypertrophy, prostate and/or breast cancer.
- Has tattooed, damaged, scarred skin or any skin condition on right or left upper arm and shoulder region that may affect absorption of drug.
- Has a clinically significant abnormal finding on the physical exam, medical history, electrocardiogram or clinical laboratory results at screening.
- Has been on a significantly abnormal diet during the 4 weeks preceding the first dose of study medication.
- Has donated blood within 56 days or plasma within 30 days prior to the first dose of study medication.
- Has participated in another clinical trial within 30 days prior to the first dose of study medication.
- Has used any over-the-counter medication, including nutritional supplements, within 7 days prior to the first dose of study medication.
- Has used any prescription medication including hormonal treatment and or supplement within 30 days prior to the first dose of study medication.
- No depot injections or drug implants within 3 months of first dose of study medication.
- Has been treated with any known drugs that are moderate or strong inhibitors/inducers of CYP enzymes such as barbiturates, phenothiazine, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication and that may impact subject safety or the validity of the study results.
- Has positive cotinine test and/or smoked or used tobacco products within 60 days prior to the first dose of study medication
- Has a positive urine screen for drugs of abuse
- Has positive alcohol breathalyzer test
- Has a positive test for Hepatitis B surface antigen, Hepatitis C antibody, or Human Immunodeficiency Virus (HIV) at screening or has been previously treated for Hepatitis B, Hepatitis C, or HIV infection.
- Any difficulty fasting or has any dietary restrictions such as lactose intolerance, vegan, low-fat, etc.
- Unavailable for any confinement days or scheduled visits.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description AndroGel AndroGel (testosterone gel) 1.62% Metered-Dose Pump AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg Testosterone Gel Testosterone Topical Gel, 1.62% Metered Pump Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
- Primary Outcome Measures
Name Time Method AUC0-t Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours Area under the concentration vs. time curve, from the time of first dosing to the time of the last measured concentration.
AUC0-inf Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours Area under the concentration vs. time curve, from time of first dosing to infinity
Cmax Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours Maximum reported concentration. Estimated for both baseline
- Secondary Outcome Measures
Name Time Method Tmax Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours Time at which Cmax is first observed
Kel Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours Apparent first order terminal elimination rate constant determined from the terminal log-linear concentration-time data
T 1/2 Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours Terminal elimination half-life
Trial Locations
- Locations (1)
Phase One Solutions, Inc.
🇺🇸Miami Gardens, Florida, United States